Home » Stocks » Endo International

Endo International PLC (ENDP)

Stock Price: $5.71 USD 0.07 (1.24%)
Updated Oct 20, 2020 10:32 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.31B
Revenue (ttm) 3.00B
Net Income (ttm) -157.57M
Shares Out 229.82M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE 2.35
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $5.71
Previous Close $5.64
Change ($) 0.07
Change (%) 1.24%
Day's Open 5.70
Day's Range 5.42 - 5.74
Day's Volume 1,564,087
52-Week Range 2.08 - 7.10

More Stats

Market Cap 1.31B
Enterprise Value 7.74B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 229.82M
Float 226.73M
EPS (basic) -0.70
EPS (diluted) -0.70
FCF / Share 1.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 23.00%
Payout Ratio n/a
Shares Short 26.83M
Short Ratio 6.31
Short % of Float 11.84%
Beta 1.33
PE Ratio n/a
Forward PE 2.35
P/FCF Ratio 4.35
PS Ratio 0.44
PB Ratio n/a
Revenue 3.00B
Operating Income 331.18M
Net Income -157.57M
Free Cash Flow 301.81M
Net Cash -6.43B
Net Cash / Share -27.98
Gross Margin 44.99%
Operating Margin 11.03%
Profit Margin -5.20%
FCF Margin 10.05%
ROA 4.54%
ROE n/a
ROIC 2.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (15)

Buy 3
Overweight 0
Hold 9
Underweight 0
Sell 3

Analyst Consensus: Hold

Price Target

$5.25*
(-8.06% downside)
Low
2.75
Current: $5.71
High
9.00
Target: 5.25
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2,9142,9473,4694,0103,2692,3812,1252,8162,5251,716
Revenue Growth-1.11%-15.04%-13.5%22.69%37.3%12.05%-24.54%11.52%47.12%-
Gross Profit1,3451,3151,2401,3751,1931,1491,2381,6801,5771,211
Operating Income74.00-417-943-3,471-997359570-540466467
Net Income-423-1,031-2,035-3,347-1,495-721-685-740188259
Shares Outstanding226224223223197147113116117116
Earnings Per Share-1.87-4.61-9.12-15.03-7.59-4.60-5.72-6.401.552.20
EPS Growth---------29.55%-
Operating Cash Flow98.05267554528119338299734702454
Capital Expenditures-63.85-83.40-126-139-81.77-80.25-94.63-98.39-57.76-19.54
Free Cash Flow34.2018442838936.73258204635644434
Cash & Equivalents1,7021,4541,3077998589371,297530548466
Total Debt8,4538,2588,2768,2738,5804,2573,7393,1673,5131,071
Net Cash / Debt-6,751-6,804-6,969-7,473-7,723-3,319-2,442-2,637-2,965-605
Assets9,39010,13211,63614,27519,35010,8246,5726,5697,2933,912
Liabilities10,25610,63111,15111,57413,3828,4165,9875,4355,2532,109
Book Value-867-4984852,7025,9682,3755261,0731,9781,742
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Endo International PLC
Country Ireland
Employees 3,172
CEO Blaise Coleman

Stock Information

Ticker Symbol ENDP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ENDP
IPO Date September 25, 1996

Description

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.